Cizzle Biotechnology Holdings PLC (GB:CIZ)
LSE:CIZ
Top Page
Cizzle Biotechnology Holdings PLC
(LSE:CIZ)
Select Model
Select Model
Rating:43Neutral
Price Target:
1.50 p
▼(-3.23% Downside)
Action:N/ADate:01/04/26
The score is held down primarily by weak financial performance (pre-revenue, ongoing losses, cash burn, and a sharply reduced equity cushion), with technical indicators also pointing to subdued momentum. Valuation metrics provide limited support due to negative earnings and no dividend.
Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£8.32M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)―
Beta (1Y)-0.21
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding396,391,780
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)73.24
Price to Sales (P/S)0.00
P/FCF Ratio-16.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model
Company Description
Cizzle Biotechnology Holdings Plc engages in development of an immunoassay test for the CIZ1B biomarker for the early detection of lung cancer. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechno...
How the Company Makes Money
Cizzle Biotechnology’s monetization is expected to come from commercializing its lung-cancer diagnostic test(s), typically through a combination of (a) selling test kits or assay components to laboratories/healthcare providers, (b) earning fees pe...
Cizzle Biotechnology Holdings PLC Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
32
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 0.00 | 0.00 | 0.00 | -963.00K | -3.96M | -306.00K |
| Net Income | -1.12K | -2.17K | -1.72K | -910.00K | -3.92M | -306.00K |
Balance Sheet | ||||||
| Total Assets | 257.00K | 492.00K | 1.69M | 2.79M | 1.16M | 90.00K |
| Cash, Cash Equivalents and Short-Term Investments | 182.00K | 387.00K | 1.56M | 478.00K | 875.00K | 84.00K |
| Total Debt | 150.00K | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K |
| Total Liabilities | 533.00K | 410.00K | 186.00K | 145.00K | 218.00K | 58.00K |
| Stockholders Equity | -276.00K | 82.00K | 1.51M | 2.64M | 937.00K | 32.00K |
Cash Flow | ||||||
| Free Cash Flow | -333.12K | -358.00K | -639.00K | -872.00K | -1.21M | -294.00K |
| Operating Cash Flow | -331.12K | -358.00K | -639.00K | -872.00K | -1.01M | -294.00K |
| Investing Cash Flow | -2.00K | 0.00 | 0.00 | -120.00K | -154.00K | 0.00 |
| Financing Cash Flow | 151.00K | 579.00K | 305.00K | 595.00K | 2.03M | 10.00 |
Cizzle Biotechnology Holdings PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | £6.23M | -0.92 | -115.97% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £4.19M | -0.88 | -53.79% | ― | ― | 85.56% | |
43 Neutral | £8.32M | -4,173.96 | -433.59% | ― | ― | ― | |
43 Neutral | £5.37M | -2.61 | -2.42% | ― | ― | ― | |
42 Neutral | £4.57M | -1.83 | -153.80% | ― | ― | -616.67% | |
41 Neutral | £2.27M | ― | ― | ― | 418.49% | 27.86% |
* Healthcare Sector Average
GB:CIZ
Cizzle Biotechnology Holdings PLC
2.10
0.55
35.48%
GB:TCF
Evgen Pharma
0.20
>-0.01
-2.50%
GB:FUM
Futura Medical
1.07
-8.61
-88.93%
GB:NFX
Nuformix Plc
0.18
0.06
49.57%
GB:OPTI
OptiBiotix Health
5.20
-11.05
-68.00%
GB:VAL
ValiRx plc
0.31
-0.17
-35.79%
Cizzle Biotechnology Holdings PLC Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cizzle Biotechnology Secures Extra Royalties as U.S. Lung Cancer Test Nears Launch
Positive
Feb 23, 2026
Cizzle Biotechnology reported progress toward the U.S. commercial launch of its CIZ1B blood test for early lung cancer detection, as North American partner Cizzle Bio Inc. nears completion of validation work with Omni Health Diagnostics in Texas a...
Business Operations and StrategyProduct-Related Announcements
Cizzle Secures Canadian Patent to Fortify Global Lung Cancer Test Rollout
Positive
Feb 4, 2026
Canadian approval for Cizzle’s CIZ1B patent reinforces the company’s proprietary two-step lung cancer test, bolstering its licensing partner Cizzle Bio Inc’s commercial rollout in North America and supporting ambitions for broade...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.